# Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)

> **NCT06025812** · NA · UNKNOWN · sponsor: **Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.** · enrollment: 160 (estimated)

## Conditions studied

- Coronavirus

## Interventions

- **BIOLOGICAL:** Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)
- **BIOLOGICAL:** Recombinant novel coronavirus protein vaccine (CHO cells)

## Key facts

- **NCT ID:** NCT06025812
- **Lead sponsor:** Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-20
- **Primary completion:** 2024-05-15
- **Final completion:** 2024-06-30
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2023-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06025812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06025812, "Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT06025812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*